CEO & INVESTOR CONFERENCE

February 10-11, 2020 • New York, NY
New York Marriott Marquis

General Overview
Advisory Committee
Education
Partnering
Investor Engagement
Company Presentations
2019 Sponsors
Sponsorship Opportunities

#BIOCEO20 • bio.org/CEO
Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies.

**Event Attributes and Opportunities**

- **Experience the best of biotech** with two-days of productive partnering meetings with institutional investors, industry analysts, and senior biotechnology executives, in one location.
- **Hear Washington’s perspective on policy** and other timely developments affecting the industry.
- **Evaluate fresh investment opportunities** including compatible, complementary, and competitive companies.
- **Learn about the hottest clinical developments** and industry catalysts by attending the conference’s therapeutic and business-focused panel discussions.
- **Attend fireside chats with senior business leaders** who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2020.
- **Gain access to BIO One-on-One Partnering™** for scouting potential investments and deal partners, optimizing your time at the event.
- **Unique platform for your company** to highlight accomplishments and discuss upcoming milestones. Approximately 170 companies will be chosen based on a selection process evaluating a company’s pipeline and R&D activities.
- **Get the pulse** of the current and proposed investment trends in biotechnology.
- **Network with peers, investors, and potential partners** attending the conference and our exclusive receptions.
- **Exclusive sponsorship opportunities** to showcase thought leadership, elevate brand identity and maximize partnering benefits with an elite audience.

---

1,200+ **ATTENDEES**

2,900+ **PARTNERING MEETINGS**

133 **COMPANY PRESENTATIONS**

650 **REGISTERED INVESTORS**

948 **PARTICIPATING COMPANIES**

33 **COUNTRIES REPRESENTED**
2020 Advisory Committee

Each year, BIO assembles a group of industry thought leaders to help us shape the conference program and provide input on key topics and themes that deliver excellence for all attendees.
**With an Air of Optimism, #BIOCEO19 Concludes**

A record number of investors—over 660—registered to learn about the latest biotech trends and to search for opportunities to turn technology into life-saving treatments. More than 130 biotechnology and pharmaceutical companies delivered 13-minute pitches showcasing their pipeline, R&D activities, business objectives and investment goals. Information was also shared through face-to-face meetings scheduled by the BIO One-on-One Partnering system which was in full swing, scheduling almost 3,000 meetings—a record for this 21st annual event.

**Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical Innovation?**

In his State of the Union address, President Trump called on Congress to “do more” to lower drug costs in the United States. Already, the U.S. Department of Health and Human Services (HHS) has proposed piloting an International Pricing Index payment model, tying costs for drugs under Medicare Part B to the lower rates paid in European benchmark countries with socialized medicine. They have moved to lower government costs for drug spending by empowering PBMs and middlemen to dramatically expand the use of utilization management tools like “fail first” that deny patients access to needed medicines. And most recently, HHS proposed changes to the drug rebate system with the goal of eliminating perverse incentives to inflate a drug’s list price. Following a year with a record number of new medicines being approved by the FDA, such reforms introduce significant uncertainty for biotech investors. The Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical Innovation? session explores the impact these moves have on biomedical investment and innovation.

**Venture Creation is in Vogue**

In the biotech industry, it’s common for a company to raise billions of dollars and wait more than a dozen years before their investors see a return. That’s why capital formation can be an arduous journey in the biotech industry. But the biotech IPO market is coming off of a hot 2018 with more than 50 biotech companies going public on the back of more than $5.4 billion in funding, marking the second-best year for biotech IPOs in a decade.

**Market Outlook—Leveraging Market Corrections for M&A or IPOs**

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of heightened market volatility. Investors’ eagerness to support new modalities enabled more than 50 biotech IPOs, but with much less mature clinical development progress than traditionally demonstrated. More than half those companies are trading below their IPO prices, however, complicating conditions for the next new offering. As interest rate worries, international trade disputes, and regulatory reimbursement uncertainty have increased, biopharma stock indexes have seen significant corrections. With historically high valuations experiencing sudden dips, M&A deal-making seems to have reignited with notable, multi-billion dollar deals in recent weeks. The Market Outlook—Leveraging Market Corrections for M&A or IPOs session brought together market experts to discuss what forces continue to shape performance within the sector and what opportunities the market correction can reveal for investors and companies seeking resources to deliver the next wave of innovative therapies for patients.

**#BIOCEO19: Navigating Payers’ Expectations for Value-Based Agreements**

Value-based agreements are becoming increasingly important in the biopharmaceutical reimbursement space, particularly as new advanced therapeutic modalities and prospective cures for diseases which previously had no comparable treatments enter the market. Yet the departure from more traditional volume-based reimbursement models poses unique difficulties for biopharmaceutical companies, payers, patients, providers, and investors in planning for a new therapy’s rollout and the breadth of patient access to it. This evolving landscape was the subject of a lively and informative discussion on the first day of the 2019 BIO CEO and Investor Conference.
Partnering

BIO One-on-One Partnering is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. Our system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives.

Attendee by Title

Company Size (employee count)

Representative Program Speakers

- Aoife Brennan, MD, CHB, Chief Executive Officer and Chief Medical Officer, Synlogic, Inc.
- Brian K. Kaspar, PhD, Chief Scientific Officer, AveXis
- Ciara Kennedy, PhD, President and Chief Executive Officer, Amplyx
- Geoff Meyerson, Managing Partner and Co-Founder, Locust Walk
- Ron Philip, Chief Commercial Officer, Spark Therapeutics
- Nancy Thornberry, Chief Executive Officer, Kallyope
- Philip Ross, Vice Chairman, J.P. Morgan
- William Slattery, Partner, Deerfield
- Erica Whittaker, PhD, Head of UCB Ventures, UCB Pharma
- Lynn O’Connor Vos, President and CEO, Muscular Dystrophy Association

Representative Companies

- Ascletis Pharma
- Alnylam Pharmaceuticals
- Celgene
- Daré Bioscience
- MaxCyte
- Mitsubishi Tanabe Pharma
- Neurotrope
- Redhill Biopharma
- Sanofi
- Vyriad

Full Program ▶

Full Company List ▶
Investor Engagement

With an industry that is rapidly and dynamically shifting, the BIO CEO & Investor Conference is a perfect balance of educational content that help investors stay attuned to issues that are relevant to peers and current/future clients while also providing an exclusive venue to source new frontiers in discovery and ensure high-quality interactions between corporate and investor colleagues.

2019 Participating Investors

- Aisling Capital
- Andreessen Horowitz
- Arch Venture Partners
- GE Ventures
- Hercules Capital
- MPM Capital
- OrbMed Advisors
- Sofinnova Ventures
- The Carlyle Group
- Vivo Capital

Representative Investors

- Aisling Capital
- Andreessen Horowitz
- Arch Venture Partners
- GE Ventures
- Hercules Capital
- MPM Capital
- OrbMed Advisors
- Sofinnova Ventures
- The Carlyle Group
- Vivo Capital

Investor Types

- Family Office (13%)
- Venture Philanthropy (22%)
- Corporate Ventures (11%)
- Other (4%)
- Venture Debt Financing (30%)
- Financial Advising – 2%
- Royalty/Debt Financing (2%)
- Venture Bank (5%)
- Angel Investing (5%)
- Sell-Side Research (11%)
- Individual Investor – 2%
Company Presentations

Opportunity for biotechnology and pharmaceutical companies to do 13-minute pitches showcasing their pipeline, R&D activities, business objectives and investment goals. Presenting companies are hand-selected for the event and consist of mid-to large-cap established public companies, and select private companies, from around the globe.

2019 PRESENTING COMPANIES

**Cardiovascular**
- Espero BioPharma
- InCarda Therapeutics
- Resverlogix Corp.
- Verseon

**CNS/Neurological**
- Anavex Life Sciences
- BioXcel Therapeutics
- Crossover Biosciences LLC
- E-Scape Bio
- EIP Pharma, Inc.
- Knopp Biosciences
- NeuroRx
- Newron Pharmaceuticals SpA
- NeNO Inc.
- ORYZON
- Otsuka Pharmaceutical
- PAION AG
- Serina Therapeutics, Inc.
- Tonix Pharmaceuticals Holding Corp.
- Trevena, Inc.
- Vallon Pharmaceuticals
- VistaGen Therapeutics, Inc.
- Zynnera Pharmaceuticals

**Dermatology**
- Azitra Inc.

**Diagnostics**
- BioMarker Strategies, LLC
- Genes2me LLP
- Intepace Diagnostics
- OncoCyte

**Digital Health**
- Congenica Ltd
- Lumme Inc

**Gastrointestinal**
- Cancer Prevention Pharmaceuticals
- Landos Biopharma
- Mirum Pharmaceuticals
- Synthetic Biologics, Inc.

**Gene/Cell Therapy**
- American Gene Technologies
- Brainstorm Cell Therapeutics
- Cesca Therapeutics Inc.
- Elexx Pharmaceuticals
- Fibrocell Science, Inc.
- MeiraGTx

**Immunology**
- Abcuro, Inc.
- aTyr Pharma, Inc.
- INmune Bio
- Immunic AG
- ImmuneSYS, Inc.

**Infectious Diseases**
- Amplyx Pharmaceuticals Inc.
- CytoDyna Inc.
- Summit Therapeutics
- VennRx Pharmaceuticals

**Medical Devices**
- Arch Therapeutics, Inc.
- CytoSorbents
- Femeda Ltd

**Metabolic Diseases**
- CohBar, Inc.
- SeraAXIS INC.

**Multiple Therapeutics**
- Amarylam Pharmaceuticals
- LifeEDIT
- Lyndra Inc
- Q BioMed Inc
- Sirnaomics, Inc

**Non-Profit/Patient Advocacy Group**
- National Health Council Patient-Centered Health Care Accelerator

**Oncology**
- Actinium Pharmaceuticals, Inc.
- AVITA Biomedical
- AUM Biosciences
- CASI Pharmaceuticals, Inc.
- CEL-SCI Corporation
- Collectar Biosciences
- Cue Biopharma
- Curis, Inc
- Cyclacel Pharmaceuticals, Inc.
- Exicure
- Greenwich LifeSciences
- Heat Biologics, Inc.
- Immunicum AB
- ImmunoMet Therapeutics
- Immunomic Therapeutics, Inc.
- IMV Inc.
- Infinity Pharmaceuticals
- Klee Pharmaceuticals
- MaxCyte, Inc.
- OncoVantis Biotech Inc.
- Onconova Therapeutics, Inc.
- OxSonics Limited
- Propanc Biopharma Inc.

**Ophthalmology**
- EyeGate Pharmaceuticals, Inc.
- Nemus Biosciences
- Nicox SA
- Ocufy, Inc.
- Orimédica
- Oyster Point Pharma, Inc.

**Orphan/Rare Diseases**
- Arcturus Therapeutics
- Catalyst Biosciences
- Catalyst Pharmaceuticals, Inc.
- Children’s Tumor Foundation
- Fulcrum Therapeutics
- Lung Therapeutics

**Other**
- Rockwell Medical, Inc
- Select Greater Philadelphia

**Platform for Therapeutics**
- Anima Biotech Inc.
- Aquestive Therapeutics
- Oramed Pharmaceuticals
- Second Genome, Inc

**Regenerative Medicine**
- Aspect Biosystems
- Caladrius Biosciences, Inc
- Carmell Therapeutics
- SpinalCyte, LLC

**Reproductive/Sexual Health**
- Daré Bioscience
- Urigen Pharmaceuticals, Inc

**Respiratory**
- ProterixBio, Inc
- Tenax Therapeutics, Inc.
- Verona Pharma

**Tools/Drug Development Support Tech**
- AbMx Biotechnology CO., LTD
- Precision NanoSystems

2019 BUZZ of BIO Winners

PUBLIC THERAPEUTIC BIOTECH
- Lumme

PRIVATE THERAPEUTIC BIOTECH
- Bioasis
- Landos Biopharma

DIAGNOSTICS AND BEYOND
- Lumme

#BIOCEO20 • bio.org/CEO
2019 Sponsors

DOUBLE HELIX SPONSORS

Bristol-Myers Squibb

Lilly

SUPPORTING BANK SPONSORS

Alliance Global Partners
BMO
HCW
ROTH

CONFERENCE SPONSORS

AlphaSense
AON
Blaise Group International

Empower Results®
Executive & Board Search

CNS
FREE MIND
IMMUNOPRECISE
Locust Walk

MARCUM
MORRISON FOERSTER
NDA
Nucleus Network

proactive investors
Servier
ShareVault
Syneos Health

THE MONEY CHANNEL

Torreya

LOCAL CO-HOST

NEW YORK BIO

#BIOCEO20 • bio.org/CEO